$Spdr S&P Biotech Etf(XBI)$ stocks usually live and die by catalysts. Clinical trial results. FDA decisions. Label updates. Drug launches. Commercial execution. For $Viridian Therapeutics, Inc.(VRDN)$, the latest catalyst is not just another trial update. It is a transformation moment. The U.S. FDA approved Lumvoa for thyroid eye disease, making it the second approved treatment in the market after Amgen’s Tepezza. More importantly, this approval gives Viridian its first commercial product. That changes the company’s identity. Before approval, Viridian was a clinical-stage biotech with potential. After approval, Viridian becomes a commercial-stage biotech with a real product to sell. That is why VRDN is
💰Stocks to watch today?(15 May)
1. What news/movements are worth noting in the market today? Any stocks to watch? 2. What trading opportunities are there? Do you have any plans? 🎁 Make a post here, everyone stands a chance to win Tiger coins!
+ Follow
+1410